Repros Therapeutics (RPRX) 2.06 $RPRX Biotechnology

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 5:19 PM

Repros Therapeutics (RPRX) 2.06 $RPRX

Biotechnology Stocks Under Investors' Scanner -- Mast Therapeutics, ZIOPHARM Oncology, Amicus Therapeutics, and Repros Therapeutics
PR Newswire - Tue Jul 26, 7:30AM CDT
Biotech firms have been battling with clinical-trial costs, pricing issues, tight policies, and economic slowdowns. However, investors and analysts remain optimistic as M&A activities continue to drive industry growth, presenting buying opportunities and reasonable dividend yields. Stock-Callers.com evaluates these equities today: Mast Therapeutics Inc. (NYSE MKT: MSTX), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Repros Therapeutics Inc. (NASDAQ: RPRX). Learn more about these stocks by accessing their freenotes at:
ZIOP: 5.06 (+0.20), MSTX: 0.36 (unch), RPRX: 2.06 (-0.06), FOLD: 6.71 (-0.01)

Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
GlobeNewswire - Wed Jun 01, 3:01PM CDT
-- EU submission on track with anticipated registration decision expected Fall 2017
RPRX: 2.06 (-0.06)

Repros Reports Positive Clinical Data for Oral Proellex(R) in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
GlobeNewswire - Wed May 18, 3:01PM CDT
-- Primary endpoint of induction of amenorrhea met for the pooled oral doses compared to placebo, p=0.0004
RPRX: 2.06 (-0.06)

Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board
GlobeNewswire - Mon May 16, 3:00PM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will serve as Chairman of the Board.
INSY: 15.91 (+0.26), RPRX: 2.06 (-0.06)

Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 40.32 (-0.18), ARQL: 1.68 (+0.02), APRI: 0.32 (+0.01), RPRX: 2.06 (-0.06)

Repros Therapeutics reports 1Q loss
Automated Insights - Tue May 10, 8:19AM CDT
WOODLANDS, Texas (AP) _ Repros Therapeutics Inc. (RPRX) on Tuesday reported a loss of $4.8 million in its first quarter.
RPRX: 2.06 (-0.06)

Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 45.29 (+0.54), BIIB: 301.83 (+11.90), CNAT: 2.29 (+0.03), AMGN: 174.16 (+2.13), RPRX: 2.06 (-0.06), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), GWPH: 96.11 (+1.79), GERN: 2.71 (+0.03), AVEO: 0.99 (-0.01), ICPT: 169.72 (-3.31), AGIO: 45.69 (+0.46), NVS: 83.07 (-0.19)

Will Repros Therapeutics (RPRX) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:56AM CDT
As of late, it has definitely been a great time to be an investor in Repros Therapeutics Inc. (RPRX).
RPRX: 2.06 (-0.06)

Repros (RPRX) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue May 03, 8:25AM CDT
With no approved products in its portfolio, investors will be focused on Repros' progress with its pipeline candidates as well as its cost projections.
OVAS: 5.24 (+0.20), JAZZ: 150.53 (-0.44), RPRX: 2.06 (-0.06), CHMA: 2.70 (+0.05)

These Four Biotech Stocks Are Trading With Massive Volume Today
ACCESSWIRE - Tue Apr 19, 9:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 19, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SGYP, RPRX, CPXX and HRTX are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CPXX: 30.24 (unch), SGYP: 4.13 (+0.05), HRTX: 16.90 (+0.28), RPRX: 2.06 (-0.06)

Trending Stocks: Investors Have Found Interest In These Four Nasdaq Stocks on Monday
ACCESSWIRE - Mon Apr 18, 11:35AM CDT
MIAMI, FL / ACCESSWIRE / April 18, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. RPRX, COOL, CLMT, and UNXL have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
UNXL: 1.27 (+0.02), COOL: 4.03 (+3.32), RPRX: 2.06 (-0.06), CLMT: 4.50 (-0.21)

Trending Stocks: Thursday's Top Trading Stock Investors Have Followed
ACCESSWIRE - Thu Apr 14, 11:07AM CDT
MIAMI, FL / ACCESSWIRE / April 14, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. COOL, SUNE, RPRX, and EXXI have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
EXXI: 0.13 (-0.01), COOL: 4.03 (+3.32), SUNE: 0.34 (unch), RPRX: 2.06 (-0.06)

4 Small Cap Stocks That Have To Be On Your Watchlist Today
ACCESSWIRE - Thu Apr 14, 7:30AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. RPRX, FELP, CLDX and FNJN are on high volume alert. We have been following RPRX and FELP all week this week. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CLDX: 4.67 (+0.05), RPRX: 2.06 (-0.06), FNJN: 1.98 (+0.04), FELP: 2.83 (+0.33)

Repros Therapeutics (RPRX) Announces Significant Data for Proellex Phase 2 Meeting with the FDA to Jointly Discuss Plans for Phase 3
ACCESSWIRE - Wed Apr 13, 12:28PM CDT
THE WOODLANDS, TX / ACCESSWIRE / April 13, 2016 / Repros Therapeutics Inc.® (NASDAQ: RPRX) reported that vaginal administration of Proellex at doses of both 6 and 12 mg achieved significant reduction in excessive menstrual bleeding, the key symptom of uterine fibroids.
RPRX: 2.06 (-0.06)

Repros Reveals Positive Data on Proellex for Uterine Fibroids
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 11:30AM CDT
Repros (RPRX) reported positive data from a phase IIb study on Proellex (vaginal administration) for the treatment of women suffering from uterine fibroids.
EBS: 30.97 (-2.42), RPRX: 2.06 (-0.06), AMAG: 27.02 (+0.49), ANIK: 50.64 (+0.72)

These Small Cap Stocks Are Getting Big Time Attention Today
ACCESSWIRE - Wed Apr 13, 9:50AM CDT
NEW YORK, NY / ACCESSWIRE / April 13, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. RPRX, FELP, EMKR and SUNE are on high volume alert. Continue reading to find out why these stocks are getting so much interest today. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
EMKR: 5.10 (-1.38), SUNE: 0.34 (unch), RPRX: 2.06 (-0.06), FELP: 2.83 (+0.33)

Repros Reports Positive Clinical Data for Vaginal Proellex(R) in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
GlobeNewswire - Tue Apr 12, 3:01PM CDT
-- Primary endpoint of induction of amenorrhea met for both vaginal doses compared to placebo, p<0.0011
RPRX: 2.06 (-0.06)

Apricus Hits 52-Week Low on Unfavorable Fispemifene Data
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 1:00PM CDT
Apricus' (APRI) shares hit a new 52-week low on disappointing top-line results from a phase IIb proof-of-concept study on fispemifene.
EBS: 30.97 (-2.42), APRI: 0.32 (+0.01), RPRX: 2.06 (-0.06), AMAG: 27.02 (+0.49)

Repros Gives EU Update on Secondary Hypogonadism Drug
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 4:05PM CDT
Repros Therapeutics (RPRX) announced that it has initiated the process for obtaining marketing authorization for enclomiphene by the European Medicines Agency.
AGN: 254.86 (+1.91), RPRX: 2.06 (-0.06), ABBV: 66.94 (+0.71)

Repros Announces Initiation of Formal Approval Process by the European Medicines Agency
GlobeNewswire - Tue Mar 15, 3:01PM CDT
Repros Therapeutics Inc.(R) (Nasdaq:RPRX) today announced that it has formally activated the process for obtaining marketing authorization for enclomiphene in the treatment of secondary hypogonadism by the European Medicines Agency (EMA).
RPRX: 2.06 (-0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

Vitamin Angels Drives Global Nutrition Advancements

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...